REACH3: Ruxolitinib in Steroid Refractory cGvHD

Opinion
Video

Dr. Zeiser discusses the recent data presented at ASH 2023 of the REACH3 trial.

Related Videos
Jamie Koprivnikar, MD, and Hana Safah, MD, experts on MDS
Jamie Koprivnikar, MD, and Hana Safah, MD, experts on MDS
Jamie Koprivnikar, MD, and Hana Safah, MD, experts on MDS
Related Content